Norman Michael Greenberg Sells 15,000 Shares of Atreca (NASDAQ:BCEL) Stock

Atreca (NASDAQ:BCEL) insider Norman Michael Greenberg sold 15,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $18.38, for a total transaction of $275,700.00. Following the completion of the transaction, the insider now directly owns 15,000 shares of the company’s stock, valued at approximately $275,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Norman Michael Greenberg also recently made the following trade(s):

  • On Thursday, May 7th, Norman Michael Greenberg sold 5,000 shares of Atreca stock. The stock was sold at an average price of $18.00, for a total transaction of $90,000.00.
  • On Friday, May 1st, Norman Michael Greenberg sold 10,000 shares of Atreca stock. The stock was sold at an average price of $15.03, for a total transaction of $150,300.00.
  • On Tuesday, April 14th, Norman Michael Greenberg sold 5,000 shares of Atreca stock. The stock was sold at an average price of $18.00, for a total transaction of $90,000.00.
  • On Wednesday, April 8th, Norman Michael Greenberg sold 8,000 shares of Atreca stock. The stock was sold at an average price of $15.01, for a total transaction of $120,080.00.
  • On Wednesday, April 1st, Norman Michael Greenberg sold 2,000 shares of Atreca stock. The stock was sold at an average price of $15.21, for a total transaction of $30,420.00.

Shares of BCEL traded up $0.20 during mid-day trading on Wednesday, hitting $18.38. 140,741 shares of the company traded hands, compared to its average volume of 201,442. Atreca has a one year low of $9.51 and a one year high of $29.35. The business has a 50-day moving average of $17.55 and a 200 day moving average of $16.59. The stock has a market capitalization of $511.50 million and a price-to-earnings ratio of -3.23.

Atreca (NASDAQ:BCEL) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.73) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.73). As a group, analysts anticipate that Atreca will post -3.07 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in Atreca by 42.0% in the first quarter. BlackRock Inc. now owns 1,863,589 shares of the company’s stock valued at $30,841,000 after buying an additional 551,189 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Atreca by 7.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 396,321 shares of the company’s stock valued at $6,132,000 after buying an additional 28,801 shares during the period. State Street Corp lifted its holdings in Atreca by 142.2% in the first quarter. State Street Corp now owns 282,909 shares of the company’s stock valued at $4,682,000 after buying an additional 166,100 shares during the period. Geode Capital Management LLC lifted its holdings in Atreca by 89.6% in the first quarter. Geode Capital Management LLC now owns 171,116 shares of the company’s stock valued at $2,831,000 after buying an additional 80,874 shares during the period. Finally, Nuveen Asset Management LLC lifted its holdings in Atreca by 772.3% in the first quarter. Nuveen Asset Management LLC now owns 138,697 shares of the company’s stock valued at $2,296,000 after buying an additional 122,797 shares during the period. Institutional investors and hedge funds own 62.14% of the company’s stock.

BCEL has been the topic of several research analyst reports. Zacks Investment Research raised shares of Atreca from a “hold” rating to a “strong-buy” rating and set a $21.00 price objective on the stock in a research note on Tuesday, May 19th. BidaskClub raised shares of Atreca from a “hold” rating to a “buy” rating in a research note on Thursday, April 16th. Robert W. Baird initiated coverage on shares of Atreca in a research note on Wednesday, April 15th. They set an “outperform” rating and a $30.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Atreca in a research note on Friday, May 15th. Finally, ValuEngine raised shares of Atreca from a “hold” rating to a “buy” rating in a research note on Thursday, March 5th. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.70.

Atreca Company Profile

Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Recommended Story: What are some reasons analysts would give stocks a buy rating?

Insider Buying and Selling by Quarter for Atreca (NASDAQ:BCEL)

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.